Phagos AI Phage Therapy Achieves 95% Accuracy and 10x Faster Discovery

Phagos has developed an AI-powered phage therapy discovery platform that achieves 95% accuracy in identifying therapeutic bacteriophages and delivers results 10 times faster than traditional phage discovery methods. The platform uses machine learning algorithms to analyze bacterial genomes, predict phage-bacteria matching patterns, and optimize phage cocktails for clinical applications. Phagos AI addresses the critical need for alternative antimicrobial treatments as antibiotic resistance continues to rise globally, positioning phage therapy as a promising precision medicine approach. The company platform automates the labor-intensive process of isolating, characterizing, and selecting phages for specific bacterial infections, enabling personalized phage treatments to be prepared in hours rather than weeks. Phagos technology has been validated in partnership with leading infectious disease research institutions and is advancing toward clinical applications for drug-resistant infections. The AI models continuously improve as more phage-bacteria interaction data becomes available, enhancing prediction accuracy and expanding the range of treatable pathogens. This use case demonstrates how AI is accelerating the development of precision antimicrobial alternatives, potentially transforming the treatment landscape for infections that no longer respond to conventional antibiotics.